China Resources Double-Crane Pharmaceutical Co Ltd (SHG:600062) — Market Cap & Net Worth

$2.71 Billion USD  · CN¥18.54 Billion CNY  · Rank #5242

Market Cap & Net Worth: China Resources Double-Crane Pharmaceutical Co Ltd (600062)

China Resources Double-Crane Pharmaceutical Co Ltd (SHG:600062) has a market capitalization of $2.71 Billion (CN¥18.54 Billion) as of May 2, 2026. Listed on the SHG stock exchange, this China-based company holds position #5242 globally and #1034 in its home market, demonstrating a -1.54% decrease in market value over the past year.

Market capitalization, also known as net worth in stock markets, is calculated by multiplying China Resources Double-Crane Pharmaceutical Co Ltd's stock price CN¥17.85 by its total outstanding shares 1038757509 (1.04 Billion). Analyse cash flow conversion of China Resources Double-Crane Pharmaceuti to see how efficiently the company converts income to cash.

China Resources Double-Crane Pharmaceutical Co Ltd Market Cap History: 2015 to 2026

China Resources Double-Crane Pharmaceutical Co Ltd's market capitalization history from 2015 to 2026. Data shows growth from $2.08 Billion to $2.71 Billion (2.64% CAGR).

Index Memberships

China Resources Double-Crane Pharmaceutical Co Ltd is a constituent of 1 market index:

Index Total Market Cap Weight (%) Rank by Market Cap
Shanghai Shenzhen CSI 300
CSI300
$4.18 Trillion 0.06% #193 of 285

Weight: China Resources Double-Crane Pharmaceutical Co Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.

China Resources Double-Crane Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline

This chart shows how China Resources Double-Crane Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.

Latest Price to Sales (P/S) Ratio

0.27x

China Resources Double-Crane Pharmaceutical Co Ltd's market cap is 0.27 times its annual revenue

Industry average: 1.04x Lower than industry average

Latest Price to Earnings (P/E) Ratio

1.85x

China Resources Double-Crane Pharmaceutical Co Ltd's market cap is 1.85 times its annual earnings

Industry average: 8.30x Lower than industry average

What These Ratios Tell Investors:

  • Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
  • Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
  • Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
  • Industry comparison provides context for whether the company is valued higher or lower than peers.
Year Market Cap (USD) Revenue (USD) Net Income (USD) P/S Ratio P/E Ratio
2015 $2.08 Billion $5.14 Billion $661.06 Million 0.41x 3.15x
2016 $2.05 Billion $5.49 Billion $714.21 Million 0.37x 2.87x
2017 $2.75 Billion $6.42 Billion $842.61 Million 0.43x 3.26x
2018 $1.62 Billion $8.23 Billion $968.59 Million 0.20x 1.67x
2019 $1.79 Billion $9.38 Billion $1.06 Billion 0.19x 1.69x
2020 $1.68 Billion $8.50 Billion $1.01 Billion 0.20x 1.67x
2021 $1.92 Billion $9.11 Billion $935.69 Million 0.21x 2.05x
2022 $2.67 Billion $9.63 Billion $1.18 Billion 0.28x 2.27x
2023 $2.83 Billion $11.31 Billion $1.67 Billion 0.25x 1.69x
2024 $3.01 Billion $11.21 Billion $1.63 Billion 0.27x 1.85x

Competitor Companies of 600062 by Market Capitalization

Companies near China Resources Double-Crane Pharmaceutical Co Ltd in the global market cap rankings as of May 2, 2026.

Key companies related to China Resources Double-Crane Pharmaceutical Co Ltd by market ranking:

  • Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
  • Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
  • Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
  • GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
Market capitalization comparison (in billions USD)
Rank Company Symbol Market Cap Price
#499 Takeda Pharmaceutical Co Ltd ADR NYSE:TAK $52.60 Billion $16.65
#525 Zoetis Inc NYSE:ZTS $50.31 Billion $114.16
#526 Jiangsu Hengrui Medicine Co Ltd SHG:600276 $50.29 Billion CN¥53.88
#572 GALDERMA GROUP AG NYSE:GALDY $45.88 Billion $42.09

China Resources Double-Crane Pharmaceutical Co Ltd Historical Marketcap From 2015 to 2026

Between 2015 and today, China Resources Double-Crane Pharmaceutical Co Ltd's market cap moved from $2.08 Billion to $ 2.71 Billion, with a yearly change of 2.64%.

Year Market Cap Change (%)
2026 CN¥2.71 Billion -2.41%
2025 CN¥2.78 Billion -7.63%
2024 CN¥3.01 Billion +6.45%
2023 CN¥2.83 Billion +5.76%
2022 CN¥2.67 Billion +39.26%
2021 CN¥1.92 Billion +14.33%
2020 CN¥1.68 Billion -6.04%
2019 CN¥1.79 Billion +10.28%
2018 CN¥1.62 Billion -41.07%
2017 CN¥2.75 Billion +34.23%
2016 CN¥2.05 Billion -1.63%
2015 CN¥2.08 Billion --

End of Day Market Cap According to Different Sources

On May 2nd, 2026 the market cap of China Resources Double-Crane Pharmaceutical Co Ltd was reported to be:

Source Market Cap
Yahoo Finance $2.71 Billion USD
MoneyControl $2.71 Billion USD
MarketWatch $2.71 Billion USD
marketcap.company $2.71 Billion USD
Reuters $2.71 Billion USD

Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.

About China Resources Double-Crane Pharmaceutical Co Ltd

SHG:600062 China Drug Manufacturers - Specialty & Generic
Market Cap
$2.71 Billion
CN¥18.54 Billion CNY
Market Cap Rank
#5242 Global
#1034 in China
Share Price
CN¥17.85
Change (1 day)
-0.61%
52-Week Range
CN¥17.70 - CN¥21.22
All Time High
CN¥33.06
About

China Resources Double-Crane Pharmaceutical Co.,Ltd. operates as a pharmaceutical company in the People's Republic of China. The company offers pharmaceutical products for blood pressure, blood sugar, injection, lipid-lowering, pediatrics, nephrology, API, pharmaceutical, psychiatry/neurology, anticoagulation, oncology, women's health, anesthesia, and analgesia. The company was founded in 1939 an… Read more